Disease duration did not influence the rates of loss of efficacy of the anti-TNF therapy in Latin American Crohn’s disease patients.

BACKGROUND/AIMS The efficacy of both Infliximab (IFX) and Adalimumab (ADA) can be reduced over time. The aim of this study was to analyze the incidence of loss of efficacy (LOE) of both IFX and ADA, and outline the influence of disease duration on its occurrence. METHODS Retrospective, multicenter, observational cohort study, with CD patients treated with… CONTINUE READING